newsfilter
← Latest News
GlobeNewswire·

Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results

FDA lifted clinical hold on IND for CP101 Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 $15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024 Corporate update ca